Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with a specific reporting date of April 12, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| April 7, 2022 | Ordinary Shares (25p each) | £17.3345 | 1,998 shares | London Stock Exchange (XLON) |
Note: Total volume is the aggregate of 4, 4, 41, 1,391, and 562 shares acquired by five individuals.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine acquisitions of ordinary shares resulting from the re-investment of dividends paid to shareholders on April 7, 2022.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of specific share transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment plans, not open market purchases or sales.
- Participants: Transactions involved Ms. S. Jackson (SVP, Global Communications), Mr. D. Jackson (PCA), Ms. V. Whyte (Company Secretary), Mr. I. Whyte (PCA), and Ms. D. Connor (PCA of President, Vaccines and Global Health).
- Share Price: The execution price for all transactions was consistent at £17.3345 per share.
- Reporting Scope: This filing does not provide quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for financial performance data.